Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 08/20/24
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial DataGlobeNewsWire • 07/25/24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 04/17/24
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingGlobeNewsWire • 04/08/24
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchGlobeNewsWire • 02/01/24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesGlobeNewsWire • 01/31/24
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyAccesswire • 01/26/24
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyGlobeNewsWire • 01/25/24
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaAccesswire • 01/18/24
Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionGlobeNewsWire • 01/17/24
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorGlobeNewsWire • 01/02/24
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024Accesswire • 12/19/23
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockGlobeNewsWire • 12/18/23
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator PatentGlobeNewsWire • 11/16/23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 11/09/23
Windtree to Present at the ThinkEquity Conference on October 19th in New York CityGlobeNewsWire • 10/12/23
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17thGlobeNewsWire • 10/10/23
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12thGlobeNewsWire • 10/03/23